Schering-Plough Corporation: Q2 1995 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1995, for Schering-Plough Corporation. The company operates primarily in pharmaceutical and health care products. A significant corporate event during this period was the completion of the sale of its worldwide contact lens business on June 28, 1995, which is now reported as a discontinued operation. Additionally, a 2-for-1 stock split was distributed on June 9, 1995, and all per-share figures reflect this adjustment.
Key Financial Metrics (Six Months Ended June 30, 1995)
| Metric | 1995 (6 Months) | 1994 (6 Months) |
|---|---|---|
| Consolidated Sales | $2,556.7 million | $2,281.9 million |
| Income from Continuing Operations | $561.0 million | $488.5 million |
| Net Income | $394.6 million | $493.9 million |
| Earnings Per Share (Continuing Ops) | $1.51 | $1.27 |
| Earnings Per Share (Total) | $1.06 | $1.28 |
| Operating Cash Flow | $386.1 million | $416.2 million |
| Cash and Equivalents (Ending) | $226.8 million | $100.7 million |
| Total Debt (Short-term + Long-term) | $938.3 million | $968.1 million |
| Effective Tax Rate | 24.5% | 24.5% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 12% ($274.8 million) year-over-year. Excluding foreign currency effects, organic growth was 9%. Domestic prescription pharmaceutical sales surged 21%, driven by CLARITIN and cardiovascular products.
- Discontinued Operations Impact: Net income decreased significantly due to a $156.2 million loss on disposal of the contact lens business. Without this charge, earnings from continuing operations grew 15%.
- Profitability: Income before taxes from continuing operations rose 15% to $743.0 million. The pre-tax margin improved to 29.1% from 28.4% in the prior year.
- Cost Structure: Cost of sales as a percentage of sales improved to 19.9% (from 20.2%) due to a favorable U.S. sales mix. SG&A expenses decreased as a percentage of sales to 37.9% (from 38.3%).
- Capital Allocation: The company repurchased $13.8 million of common shares in the first half of 1995 and paid $202.8 million in dividends. A new $500 million share repurchase program was authorized in June 1995.
Outlook, Risks, and Management Commentary
- Guidance: Management anticipates total research and development expenses to approximate $650 million for the full year 1995.
- Market Risks:
- Domestic: Increasing pressure from managed care groups and government agencies for price discounts. Future health care reform proposals pose uncertainty.
- International: Government-mandated cost containment programs, particularly in Japan (affecting INTRON A sales) and across-the-board price cuts in other markets.
- Competition: Anticipated entry of generic albuterol inhalers is expected to negatively affect PROVENTIL sales and profitability.
- Legal Contingencies:
- THEO-DUR Litigation: A $63.6 million judgment (including $57.5 million punitive damages) was entered in 1994. The company is appealing and has sued its insurance carriers regarding coverage for punitive damages.
- Antitrust Actions: The company is a defendant in over 145 antitrust actions alleging price discrimination and conspiracy. Plaintiffs seek unspecified treble damages. Management believes these claims are without merit.
Investor Verification Checklist
- Verify the status of the appeal regarding the $63.6 million THEO-DUR judgment and the outcome of the lawsuit against insurance carriers.
- Monitor the timeline for generic albuterol inhaler market entry and its specific impact on PROVENTIL revenue.
- Assess the progress of the new $500 million share repurchase program authorized in June 1995.
- Review the impact of foreign currency exchange rates on international sales, as organic growth (9%) was lower than reported growth (12%).
- Track the resolution of the 145+ antitrust actions and potential exposure to treble damages.